March 25, 2017 10:31 PM ET

Capital Markets

Company Overview of Objective Capital Partners, LLC

Company Overview

Objective Capital Partners, LLC is a mergers and acquisitions advisory firm. The firm provides buy-side and sell-side advisory including exit preparation and price maximization. It also provides early stage financing, debt financing, growth equity, transaction evaluation and alternative review, and faimess opinions. The firm serves closely held businesses with revenues in the range between $10 million to $250 million. Objective Capital Partners, LLC was founded in 2005 and is based in San Diego, California.

3636 Nobel Drive

Suite 160

San Diego, CA 92122

United States

Founded in 2005

Phone:

858-663-8662

Key Executives for Objective Capital Partners, LLC

Managing Director
Managing Director
Managing Director
Director
Vice President
Compensation as of Fiscal Year 2016.

Objective Capital Partners, LLC Key Developments

Regen BioPharma, Inc. Retains Objective Capital Partners, LLC as Advisor

Regen BioPharma Inc. announced that it has retained Objective Capital Partners, LLC as its advisor to assist the company in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide a source of non-dilutive funding.

Avacen Retains Adviser To Find Qualified Purchaser

AVACEN, Inc. has formally retained Objective Capital Partners, LLC to locate a qualified purchaser to acquire the company. Thomas G. Muehlbauer, Chief Executive Officer of AVACEN, Inc., said, "Of the alternatives we explored, the Company has determined it is in the best interest of its shareholders to offer itself as an acquisition target to a buyer that possesses the necessary resources to advance our fields of use and support the worldwide demand for the Company's products. We believe this is the most advantageous and quickest path to secure our $10 Billion annual sales potential while the 17 year average remaining term of our U.S. and International patents is most favorable."

Objective Capital Partners, LLC Adds David Crean as a Managing Director to Lead its Life Sciences Investment Banking Practice

Objective Capital Partners, LLC announced that it has added Dr. David Crean as a Managing Director to lead its life sciences investment banking practice. Prior to joiningObjective Capital Partners, Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan and Aqua Pharmaceuticals.

Similar Private Companies By Industry

Company Name Region
@Visory LLC United States
1 Road Partners LLC United States
11T Partners, LLC United States
123Jump.com, Inc. United States
1509225 Ontario, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Objective Capital Partners, LLC, please visit www.objectivecp.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.